Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 2
2013 1
2014 3
2015 7
2016 14
2017 24
2018 24
2019 21
2020 28
2021 36
2022 38
2023 43
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
Kircik LH, Stein Gold L, Gold M, Weiss JS, Harper JC, Del Rosso JQ, Bunick CG, Bhatia N, Tanghetti EA, Eichenfield LF, Baldwin H, Draelos ZD, Callender VD, Han G, Gooderham MJ, Sadick N, Lupo MP, Lain ET, Werschler WP. Kircik LH, et al. Among authors: gooderham mj. Dermatol Ther (Heidelb). 2024 May 9. doi: 10.1007/s13555-024-01155-7. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38724841
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Simpson EL, et al. Among authors: gooderham m. Dermatol Ther (Heidelb). 2024 May 3. doi: 10.1007/s13555-024-01158-4. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38700646
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Egeberg A, et al. Among authors: gooderham m. Dermatol Ther (Heidelb). 2024 Apr;14(4):1007-1018. doi: 10.1007/s13555-024-01147-7. Epub 2024 Apr 22. Dermatol Ther (Heidelb). 2024. PMID: 38647975 Free PMC article.
Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients.
Jeremian R, Lytvyn Y, Fotovati R, Li K, Malinowski A, Sachdeva M, Jack C, Gooderham M, Croitoru DO, Yeung J, Piguet V. Jeremian R, et al. Among authors: gooderham m. J Eur Acad Dermatol Venereol. 2024 Apr 15. doi: 10.1111/jdv.19978. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38619335 No abstract available.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, Hong HC, Kempers SE, Kircik LH, Lebwohl M, Loo WJ, Nahm WK, Papp KA, Stewart D, Toth DP, Zirwas M, Krupa D, Snyder S, Burnett P, Higham R, Berk DR. Stein Gold L, et al. Among authors: gooderham mj. J Am Acad Dermatol. 2024 Mar 29:S0190-9622(24)00541-3. doi: 10.1016/j.jaad.2024.03.030. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38556093 Free article.
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry.
Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Silverberg JI, et al. Among authors: gooderham m. JAAD Int. 2024 Feb 12;15:127-130. doi: 10.1016/j.jdin.2023.11.015. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38545488 Free PMC article. No abstract available.
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D. Silverberg JI, et al. Among authors: gooderham mj. Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25. Am J Clin Dermatol. 2024. PMID: 38528257 Free PMC article. Clinical Trial.
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey.
Lee EY, Turchin I, Chan AW, Beecker J, Bissonnette R, Catherall H, Cresswell-Melville A, Gooderham M, Hawkins N, Hong HC, Levell NJ, Lapointe McKenzie JA, Manion R, Papp K, Drucker AM. Lee EY, et al. Among authors: gooderham m. J Cutan Med Surg. 2024 Mar 19:12034754241239260. doi: 10.1177/12034754241239260. Online ahead of print. J Cutan Med Surg. 2024. PMID: 38504147 No abstract available.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M, Vender R, Crowley J, Hong HC, Feely M, Garrelts A, See K, Konicek B, Green L. Gooderham M, et al. Dermatol Ther (Heidelb). 2024 Feb;14(2):441-451. doi: 10.1007/s13555-023-01075-y. Epub 2024 Feb 9. Dermatol Ther (Heidelb). 2024. PMID: 38332436 Free PMC article.
217 results